Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plavix Generic Faces Injunction, But Not Recall

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex is filing emergency appeal to stay the injunction after Bristol and Sanofi win in U.S. district court.

You may also be interested in...



Bristol May Have Grounds For Fraud Case Against Apotex – Attorney

Wiley Rein & Fielding partner says Bristol-Myers Squibb may have a case against Apotex for sabotaging the Plavix settlement deal.

Bristol May Have Grounds For Fraud Case Against Apotex – Attorney

Wiley Rein & Fielding partner says Bristol-Myers Squibb may have a case against Apotex for sabotaging the Plavix settlement deal.

Plavix Patent Infringement Trial Set For Jan. 22

Sanofi/Bristol demonstrated that Apotex patent invalidity defense "lacks substantial merit," according to a court ruling granting a preliminary injunction blocking generics.

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel